Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

About Scott Martin

Scott Martin Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Scott Martin News

Domainex appoints Dr Scott Martin as Analytical and Bioanalytical Group Leader

May 12, 2022

Domainex appoints Dr Scott Martin as Analytical and Bioanalytical Group Leader Cambridge, UK, 12th May 2022 /  Sciad Newswire  /  Domainex Ltd , a leading integrated medicines research services partner, is pleased to announce that Dr Scott Martin has been appointed Analytical and Bioanalytical Group Leader with immediate effect. His appointment will strengthen Domainex’s rapidly expanding team of international scientists and follows the announcement of Domainex’s purchase of over £1M worth of new Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays. “I am delighted to join Domainex,” said Dr Martin. “I’m looking forward to leading the expanding team and creating innovative solutions to develop new services and capabilities and optimising our existing offerings. The newly equipped labs have everything the team needs and will be a great place to work.” Dr Martin has 25 years of experience in bioanalytical/analytical mass spectrometry within drug discovery and development, predominately gained in large pharma. He has successfully supported projects throughout the drug discovery and development process by driving scientific innovation, matrix managing teams and providing expert opinion in the fields of biotransformation and bioanalysis. Before joining Domainex, Dr Martin worked for AstraZeneca for 20 years as an associate principal scientist within the Oncology DMPK department. Previously, he has held positions in analytical/bioanalytical science at Roche, GlaxoWellcome, Zeneca Agrochemicals and a large contract research organisation (CRO). “I’m thrilled to welcome Scott to Domainex,” commented Dr Tom Mander, CEO of Domainex. “His wealth of experience will be invaluable in helping Domainex further strengthen its analytical chemistry and bioanalytical team. The team is expanding rapidly, and Scott’s experience makes him the ideal candidate to guide the group during this exciting period of growth. So far this year, 16 recruits have joined the Domainex team, and I would like to take this opportunity to welcome these new staff members.”   ENDS About Domainex Ltd. Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally. Domainex provides innovative and customised biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for its partners’ research. Domainex’s innovative science and extensive technical capabilities enable it to produce novel candidate medicines to treat debilitating diseases. The team works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how and a wealth of experience to bear on their projects. Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs. The Company aims to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research. Full information about Domainex and its award-winning services can be found at www.domainex.co.uk . For more information, please contact: Domainex

Scott Martin Investments

1 Investments

Scott Martin has made 1 investments. Their latest investment was in Kira Talent as part of their Seed VC on December 12, 2012.

CBI Logo

Scott Martin Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/11/2012

Seed VC

Kira Talent

Yes

2

Date

12/11/2012

Round

Seed VC

Company

Kira Talent

Amount

New?

Yes

Co-Investors

Sources

2

Scott Martin Portfolio Exits

1 Portfolio Exit

Scott Martin has 1 portfolio exit. Their latest portfolio exit was Kira Talent on November 11, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/11/2021

Acq - Fin

2

Date

11/11/2021

Exit

Acq - Fin

Companies

Valuation

Acquirer

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.